Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events
Cancers · 06.03.2023 · 15 (5) · 1629
DOI: 10.3390/cancers15051629 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 06.03.2023. Verfasst von Iñigo Les und 10 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine Department, Navarre University Hospital, 31008 Pamplona, Spain. Die Arbeit wurde bisher 106-mal zitiert (Crossref) und nennt 227 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Basque Government.
Themen: Patientensicherheit
Abstract (Originalsprache)
Immune-checkpoint inhibitors (ICIs) are antagonists of inhibitory receptors in the immune system, such as the cytotoxic T-lymphocyte-associated antigen-4, the programmed cell death protein-1 and its ligand PD-L1, and they are increasingly used in cancer treatment. By blocking certain suppressive pathways, ICIs promote T-cell activation and antitumor activity but may induce so-called immune-related adverse events (irAEs), which mimic traditional autoimmune disorders. With the approval of more ICIs, irAE prediction has become a key factor in improving patient survival and quality of life. Several biomarkers have been described as potential irAE predictors, some of them are already available for clinical use and others are under development; examples include circulating blood cell counts and ratios, T-cell expansion and diversification, cytokines, autoantibodies and autoantigens, serum and other biological fluid proteins, human leucocyte antigen genotypes, genetic variations and gene profiles, microRNAs, and the gastrointestinal microbiome. Nevertheless, it is difficult to generalize the application of irAE biomarkers based on the current evidence because most studies have been retrospective, time-limited and restricted to a specific type of cancer, irAE or ICI. Long-term prospective cohorts and real-life studies are needed to assess the predictive capacity of different potential irAE biomarkers, regardless of the ICI type, organ involved or cancer site.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Internal Medicine Department, Navarre University Hospital, 31008 Pamplona, Spain.
- Autoimmune Diseases Unit, Internal Medicine Department, Navarre University Hospital, 31008 Pamplona, Spain.
- Inflammatory and Immune-Mediated Diseases Group, Instituto de Investigación Sanitaria de Navarra (IdISNA), Navarrabiomed-Public University of Navarre, 31008 Pamplona, Spain.
- Osakidetza Basque Health Service, Department of Medical Oncology, Araba University Hospital, 01009 Vitoria-Gasteiz, Spain.
- Lung Cancer Research Group, Bioaraba Health Research Institute, 01006 Vitoria-Gasteiz, Spain.
- Breast Cancer Research Group, Bioaraba Health Research Institute, 01006 Vitoria-Gasteiz, Spain.
ORCID-Profile: Mireia Martínez, Ana Campillo-Calatayud, David Escors
Förderung
- Basque Government
Zitieren
APA
Les, I., Martínez, M., Pérez-Francisco, I., Cabero, M., Teijeira, L., Arrazubi, V., Torrego, N., Campillo-Calatayud, A., Elejalde, I., Kochan, G., & Escors, D. (2023). Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events. Cancers, 15(5), 1629. https://doi.org/10.3390/cancers15051629
Vancouver
Les I, Martínez M, Pérez-Francisco I, Cabero M, Teijeira L, Arrazubi V, et al. Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events. Cancers. 2023;15(5):1629. doi:10.3390/cancers15051629
BibTeX
@article{Les2023,
author = {Les, Iñigo and Martínez, Mireia and Pérez-Francisco, Inés and Cabero, María and Teijeira, Lucía and Arrazubi, Virginia and Torrego, Nuria and Campillo-Calatayud, Ana and Elejalde, Iñaki and Kochan, Grazyna and Escors, David},
title = {Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events},
journal = {Cancers},
year = {2023},
volume = {15},
number = {5},
pages = {1629},
doi = {10.3390/cancers15051629}
}
EUVIMED